Drug recall · March 11, 2026
Nilotinib Capsules recall
Why: Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17
- Lots / codes
Lot #: 5GJ0223, Exp 04/30/2027
- Quantity
- 164 cartons
- Company
- Cipla USA, Inc., Warren, NJ
- Distribution
- U.S.A. Nationwide
- Initiated
- February 18, 2026 · Voluntary: Firm initiated
- Classified
- March 3, 2026
- Reported
- March 11, 2026
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.